Literature DB >> 6209201

Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes.

C B Reimer, D J Phillips, C H Aloisio, D D Moore, G G Galland, T W Wells, C M Black, J S McDougal.   

Abstract

Stable clones of 31 mouse hybridomas that produce monoclonal antibodies (MAbs) against human IgG antigenic determinants were obtained. The number of hybridomas of different specificity described are: 2 anti-IgG1 Fc, 1 anti-IgG2 Fc, 1 anti-IgG2 Fd, 2 anti-IgG3 Fc, 2 anti-IgG3 hinge, 3 anti-IgG4 Fc, 3 anti-IgG4 Fd, 2 anti-nG4m(b), 4 anti-IgGFc, 2 anti-IgGFd, 1 anti-kappa, 1 anti-lambda, 1 anti-non IgG1, 2 anti-non IgG2, 2 anti-non-IgG3, 2 anti-non-IgG4. Evidence is presented validating their specificity. Some MAbs demonstrated to be avid, potent, and specific for well defined IgG-subclass epitopes may be partially or completely inactive in other assay systems, presumably because of different presentations of antigen epitopes. In general, this problem requires careful writing of protocols describing the use of MAbs.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6209201     DOI: 10.1089/hyb.1984.3.263

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  33 in total

1.  Multiple levels of analysis of an IGHG4 gene deletion.

Authors:  A Bottaro; U Cariota; G G de Lange; M DeMarchi; R Gallina; S Oliviero; A Vlug; A O Carbonara
Journal:  Hum Genet       Date:  1990-12       Impact factor: 4.132

2.  The distribution of IgG subclass autoantibodies in bullous pemphigoid analysed by immunofluorescence and immunoblotting.

Authors:  H Soh; H Hosokawa; H Miyauchi; H Izumi; Y Asada
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

3.  Immunogenic and antigenic epitopes of immunoglobulins. XVIII. Subpopulations of human lambda chains defined with a panel of monoclonal antibodies.

Authors:  M R Walker; A Solomon; N R Ling; B Brown; J A Lowe; D Hardie; R Jefferis
Journal:  Immunology       Date:  1986-11       Impact factor: 7.397

4.  Immunoblot analysis of humoral immune responses following infection with Bordetella pertussis or immunization with diphtheria-tetanus-pertussis vaccine.

Authors:  S C Redd; H S Rumschlag; R J Biellik; G N Sanden; C B Reimer; M L Cohen
Journal:  J Clin Microbiol       Date:  1988-07       Impact factor: 5.948

5.  Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.

Authors:  S E Maslanka; J W Tappero; B D Plikaytis; R S Brumberg; J K Dykes; L L Gheesling; K B Donaldson; A Schuchat; J Pullman; M Jones; J Bushmaker; G M Carlone
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

6.  Subclass restriction of human enterovirus antibodies.

Authors:  E G Torfason; C B Reimer; H L Keyserling
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

7.  Facile development of medium optimization for antibody production: implementation in spinner flask and hollow fiber reactor.

Authors:  Chi-Hsien Liu; Yi-Xin Liu; Wei-Chi Wu
Journal:  Cytotechnology       Date:  2018-10-03       Impact factor: 2.058

8.  IgG subclass distribution and relative functional affinity of anti-myeloperoxidase antibodies in systemic vasculitis at presentation and during follow-up.

Authors:  V L Esnault; D R Jayne; A P Weetman; C M Lockwood
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

9.  A milk-free diet downregulates folate receptor autoimmunity in cerebral folate deficiency syndrome.

Authors:  Vincent T Ramaekers; Jeffrey M Sequeira; Nenad Blau; Edward V Quadros
Journal:  Dev Med Child Neurol       Date:  2008-03-19       Impact factor: 5.449

10.  Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum.

Authors:  V A Semenova; E Steward-Clark; K L Stamey; T H Taylor; D S Schmidt; S K Martin; N Marano; C P Quinn
Journal:  Clin Diagn Lab Immunol       Date:  2004-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.